Västra Hamnen Corporate Finance Initiates Research Coverage of ViroGates

Wed Jan 29 2020

The analysis comprises an independent review of the Company, its products, markets and competitors as well as a financial scenario that constitutes the basis of an estimated justified market capitalization of ViroGates.

The research coverage is governed by an agreement made between ViroGates and Västra Hamnen Corporate Finance.

In its initiation coverage report, Västra Hamnen Corporate Finance AB concludes that the suPARnostic® biomarker is;

“A simple blood test to immensely improve clinical decision making …. with global market opportunities and virtually no competition”

and

“Our DCF model suggests a fair value range for the stock price of DKK 68.00 – DKK 100.50 given our current view of the risk and including only the Acute Care market in our model.

We see potential for further valuation upgrades when the company has overcome certain risks and when it gets closer to addressing other market segments.”

Please find the Initial Research Report here;

ViroGates – A suPAR Highway to Health 20200129

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates